Al18F-NOTA-FAPI

DRUG2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions

Aggressive LymphomaMalignancy

Phase 2

Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins

RecruitingNCT05749302

Cancer Institute and Hospital, Chinese Academy of Medical SciencesMalignancy

Start: 2023-01-08End: 2026-01-08Target: 500Updated: 2024-03-29

Unknown Phase

Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study

RecruitingNCT07657494

Cancer Institute and Hospital, Chinese Academy of Medical SciencesAggressive Lymphoma

Start: 2024-07-11End: 2026-12-31Target: 94Updated: 2026-06-18